Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07437313 · ClinicalTrials.gov registry record · NA
Marine Lipids Ease Painful TMD
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Not yet
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT07437313 is a NA study that has not yet begun recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 100 participants.
The verdict
NCT07437313, a NA study, has not yet begun recruiting, sponsored by University of North Carolina, Chapel Hill.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The ADAPT study is a single-site, Phase 2b, randomized, quadruple-masked, placebo-controlled trial evaluating an omega-3 dietary supplement enriched with specialized pro-resolving mediator (SPM) precursors in adults with chronic temporomandibular disorder (TMD) pain. The trial will enroll 100 adults aged 18 years or older with examiner-confirmed TMD myalgia or arthralgia will be enrolled at the University of North Carolina at Chapel Hill, Adams School of Dentistry. Participants are randomized 1:1 to receive either the SPM precursor supplement or a matched placebo daily for 8 weeks. Randomization is stratified by sex, and study agents are identical in appearance to maintain masking. The study aims to evaluate whether the SPM precursor supplement: Reduces facial pain intensity compared with placebo. Changes pressure pain sensitivity at the jaw and other standard body sites. Affects other aspects of chronic pain, including duration, interference with daily activities, headache burden, anxiety, depression, jaw-related quality of life, and overall patient-reported change. Participants will record their daily facial pain intensity in electronic diaries, complete short questionnaires at baseline, Week 4, and Week 8, and undergo experimental pain testing with a handheld algometer at baseline, Week 4, and Week 8. Safety is monitored through the documentation of all adverse events throughout the study period.
Interventions
- DIETARY_SUPPLEMENT SPM Precursor-Enriched Marine Lipid Supplement
- DIETARY_SUPPLEMENT Medium-Chain Triglyceride Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-08 |
| Est. Completion | 2030-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07437313
The ClinicalTrials.gov registry entry for NCT07437313 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SPM Precursor-Enriched Marine Lipid Supplement is the first listed.
NCT07437313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07437313 about?
NCT07437313 is a clinical study titled "Marine Lipids Ease Painful TMD". The ADAPT study is a single-site, Phase 2b, randomized, quadruple-masked, placebo-controlled trial evaluating an omega-3 dietary supplement enriched with specialized pro-resolving mediator (SPM) precursors in adults with chronic temporomandibular disorder (TMD) pain. The trial will enroll 100 adults...
What is the current status of trial NCT07437313?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-08. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07437313?
The interventions under investigation include: SPM Precursor-Enriched Marine Lipid Supplement (DIETARY_SUPPLEMENT), Medium-Chain Triglyceride Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07437313?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.